510(k) Report

510(k) · Cleared

Cleared

KetoSens BT Blood B-Ketone Monitoring System

K201551510(k) SpecialCleared Sep 9, 202092-day reviewClass I21 CFR 862.1435

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

I-Sens, Inc. · JIN Nitroprusside, Ketones (Urinary, Non-Quant.)

Cleared on Sep 9, 2020 after a 92-day review. FDA’s file for it is a 510(k) statement, which names no predicate.

Decided
Sep 9, 2020
Review
92 days
Class
Class I
Product code
JIN
Recalls
None
Predicates
0

FDA’s file for it is a 510(k) statement, which names no predicate.

FIG. 1 — Lineage of K201551Source: FDA 510(k) database · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA 510(k) statement (indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in JIN? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new JIN device

  1. #1 K192957 VivaChek Blood Glucose and B-Ketone Monitoring…score 1.6 · 8 generations · no Class I recall
Get a 510(k) Report

What was it cleared against?

FDA’s file for it is a 510(k) statement, which names no predicate.

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

How does its category compare?

All JIN devices

JIN Nitroprusside, Ketones (Urinary, Non-Quant.): FDA decisions, review times, recalls and adverse event reports over 20 years. 2020, this device’s year, is highlighted.

FDA decisions per year · JIN

2in 2020

2017: 12018: 32020: 2
2007high 3 (2018) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · JIN

192in 2018

2018: 192 days median
2007high 192 (2018)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · JIN

3in 2023

2022: 12023: 32026 (partial year): 1
2007high 3 (2023) · low 0 (2007)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · JIN

4in 2025

2011: 12015: 12018: 52019: 522020: 372021: 432022: 142023: 172024: 72025: 4
2007high 52 (2019) · low 0 (2007)2025

MAUDE reports naming product code JIN, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—00
20080—00
20090—00
20100—00
20110—01
20120—00
20130—00
20140—00
20150—01
20160—00
20171—00
2018319205
20190—052
20202—037
20210—043
20220—114
20230—317
20240—07
20250—04
20260—1—

What is it indicated for?

The KetoSens BT Blood β-Ketone Monitoring System is intended for the quantitative measurement of β-Ketone (betahydroxybutyrate) level in capillary whole blood drawn from the fingertip. The KetoSens BT Blood β-Ketone Monitoring System is intended for self-testing outside the body (in vitro) by people with diabetes at home as an aid to monitor the effectiveness of ketoacidosis control. The system is not intended for use in the diagnosis of or screening for…

Read the full statement (124 words)

The KetoSens BT Blood β-Ketone Monitoring System is intended for the quantitative measurement of β-Ketone (betahydroxybutyrate) level in capillary whole blood drawn from the fingertip. The KetoSens BT Blood β-Ketone Monitoring System is intended for self-testing outside the body (in vitro) by people with diabetes at home as an aid to monitor the effectiveness of ketoacidosis control. The system is not intended for use in the diagnosis of or screening for ketoacidosis and is not intended for use on neonates. This system is intended to be used by a single person and should not be shared.

The KetoSens Blood β-Ketone Test Strips work with the KetoSens BT Blood β-Ketone Meter to quantitatively measure Blood β-Ketone in capillary whole blood samples drawn from the finger.

Indications for use as stated in the FDA 510(k) statement.

Cite this page

510(k) Report. “K201551: KetoSens BT Blood B-Ketone Monitoring System.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K201551

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Page last updated Nov 3, 2026